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Intravitreal Avastin for macular oedema secondary to retinal vein
occlusion: a prospective study
Abstract
OBJECTIVE: To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in eyes with
macular oedema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion
(BRVO). METHODS: Twenty-eight consecutive patients (28 patients, 29 eyes, 8 CRVO, 21 BRVO)
were enrolled in the study. Three intravitreal injections of 1 mg bevacizumab (0.04 ml) were
administered at 4-week intervals; further retreatment was based on optical coherence tomography (OCT)
findings. Follow-up examinations were done at days 1, 7 and 28 and at monthly intervals thereafter.
RESULTS: Mean baseline central retinal thickness (CRT) in OCT was 558 microm (range 353-928
microm) and mean BCVA was 20/100. One day after the first injection, CRT significantly decreased to
401 microm (p<0.01). Three injections reduced macular oedema to 328 microm CRT (p<0.01) and
improved BCVA to 20/50 (p<0.01). At 6 months, CRT was 382 microm (p<0.01), and BCVA was
stable at 20/50(-2) (p<0.01), FA showed no evidence of increased avascular zones. CONCLUSION:
Intravitreal injections of bevacizumab appear to be a safe and effective therapy in the treatment of
macular oedema secondary to retinal vein occlusion.
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Abstract 
 
Objective: To evaluate efficacy and safety of intravitreal bevacizumab (Avastin) in 
eyes with macular edema secondary to central (CRVO) or branch retinal vein 
occlusion (BRVO). 
Methods: Twenty-eight consecutive patients (28 patients, 29 eyes, 8 CRVO, 21 
BRVO) were enrolled in the study. Three intravitreal injections of 1 mg bevacizumab 
(0.04 ml) were administered at 4 week intervals; further retreatment was based on 
optical coherence tomography (OCT) findings. Follow-up examinations were done at 
days 1, 7 and 28 and at monthly intervals thereafter.  
Results: Mean baseline central retinal thickness (CRT) in OCT was 558 µm (range 
353 to 928 µm) and mean BCVA was 20/100. One day after the first injection, CRT 
significantly decreased to 401 µm (p < 0.01). Three injections reduced macular 
edema to 328 µm CRT (p < 0.01) and improved BCVA to 20/50 (p < 0.01). At 6 
month CRT was 382 µm (p < 0.01), and BCVA was stable at 20/50 -2 (p < 0.01), FA 
showed no evidence of increased avascular zones.  
Conclusion: Intravitreal injections of bevacizumab appear to be a safe and effective 
therapy in the treatment of macular edema secondary to retinal vein occlusion.  
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Introduction 1 
 2 
A very common finding of retinal vein occlusions is a chronic macular edema, which 3 
is in part responsible for severe visual impairment. Several therapeutic options are 4 
currently in clinical use. The Branch Vein Occlusion Study 1recommended a grid 5 
pattern lasercoagulation for selected branch retinal vein occlusion (BRVO). However, 6 
this treatment strategy is not recommended for central retinal vein occlusion 7 
(CRVO).2 Intravitreal injections of corticosteroids have been increasingly used,3-5 but 8 
the treatment success is limited by ocular complications.4-9 Several surgical 9 
techniques 10-12 are still controversial and have not yet been sufficiently supported by 10 
randomized clinical trials.  11 
With the introduction of anti-vascular endothelial growth factor (VEGF) therapy for the 12 
treatment of ocular diseases, several anti-VEGF drugs appear promising for 13 
CRVO/BRVO. Since retinal vein occlusions are associated with increased levels of 14 
VEGF in the vitreous 13,14, and VEGF has been shown to play a major role in the 15 
development of macular edema 13, the inhibition of VEGF could be of therapeutic 16 
value.  17 
Bevacizumab (Avastin ®, Genentech, San Francisco, USA / Hoffmann La Roche, 18 
Basel, Switzerland), a recombinant monoclonal antibody binding all isoforms of 19 
VEGF, is approved for cancer therapy and available for off-label use in 20 
ophthalmology. Several retrospective case series and short term prospective studies 21 
have analyzed the effect of intravitreal bevacizumab for BRVO and CRVO, showing 22 
promising functional and anatomic results.15- 20 23 
Our prospective study evaluated the effect of intravitreal bevacizumab on macular 24 
edema secondary to retinal vein occlusion.  25 
 26 
Patients und Methods 27 
 28 
This prospective, uncontrolled study was conducted at the department of 29 
ophthalmology at the Medical University of Vienna and enrolled 28 consecutive 30 
patients (29 eyes). The study was approved by the ethics committee at the Medical 31 
University of Vienna, registered at the European clinical database (EUDRACT-2005-32 
003288-21) and followed the tenets of the Helsinki protocol. Informed consent was 33 
obtained from all patients.  34 
 35 
Change in mean best corrected visual acuity (BCVA) was defined as primary study 36 
outcome. Secondary outcomes were change in the 1 mm central retinal thickness 37 
(CRT) as measured by optical coherence tomography (Stratus OCT™, Carl Zeiss 38 
Meditec AG, Jena, Germany), number of treatments, ocular and systemic safety, 39 
progression of avascular areas by fluorescein angiography (FA), and the incidence of 40 
neovascular complications.  41 
 42 
For study inclusion BCVA measured by Early Treatment Diabetic Retinopathy Study 43 
(ETDRS) charts at 2 meter distance 21 had to be between 20/800 and 20/25. Patients 44 
with BRVO and a BCVA of 20/50 or worse had either prior grid laser coagulation or 45 
were offered grid laser coagulation. Out of the patient population presenting with 46 
BRVO, 4 patients had laser coagulation prior to study inclusion. None of the BRVO 47 
patients suitable for grid laser coagulation agreed to such treatment after full 48 
informed consent. CRVO patients had no laser treatment prior to study inclusion.  49 
 The CRT as measured by OCT had to exceed 250 µm due to cystoid macular 50 
edema involving the foveal center. Exclusion criteria were signs of non perfusion or 51 
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ischemia, defined as neovascularisation on the disc or elsewhere, rubeosis or more 52 
than 10 disc areas of non-perfusion detected by FA (Heidelberg Retina Angiograph 53 
II, Heidelberg Engineering, Heidelberg, Germany). Each angiogram was interpreted 54 
by the authors SM and MG. To await spontaneous improvement and to exclude a 55 
potentially negative effect of anti-VEGF therapy on formation of collaterals the 56 
duration of the RVO had to be longer than 3 months before treatment initiation. 57 
Follow-up examinations were performed one day, one week, and one month after the 58 
first injection and in monthly intervals thereafter. Each patient underwent a baseline 59 
screening including BCVA, measurement of CRT, FA, and slit lamp biomicroscopy. 60 
Repeated OCT, BCVA testing and slit lamp examination was performed at each 61 
study visit. FA was performed at three month intervals.  62 
Each patient received three initial intravitreal injections of 1 mg bevacizumab 63 
(0.04ml) at four week intervals. Injections were performed under sterile conditions in 64 
the operating room according to the national recommendations.22 Bevacizumab was 65 
prepared under sterile conditions by the University Hospital pharmacy and filled into 66 
sterile tuberculin syringes, each containing 0.2 ml (5 mg). A volume of 0.04 ml of 67 
bevacizumab was injected via the pars plana into the vitreous using a 30g needle.  68 
After three initial injections retreatment was indicated whenever persistent or 69 
recurrent intraretinal edema was documented by OCT. No repeated injection was 70 
indicated in case of progression of avascular areas by more than 3 disc areas. 71 
   72 
Statistical analyses 73 
Changes in BCVA and CRT are presented as mean (and range). BCVA is reported in 74 
letters read on ETDRS charts and their Snellen equivalent. The paired t-test was 75 
applied for data with normal distribution. A value of p < 0.05 was considered as 76 
statistically significant. For correlations, Pearson Test was used and specified by 77 
coefficient “r” and by “p” for significance.   78 
 79 
Results: 80 
Fifteen female and 13 male participants were enrolled in the study (mean age: 66 81 
years). One patient presented with BRVO in both eyes. Eight eyes presented with 82 
CRVO, 21 eyes with BRVO. Two patients were excluded at month 3 due to reasons 83 
unrelated to their ocular disease. During the 6 month follow-up period, each patient 84 
received a mean of 5.3 out of 7 possible injections. All patients received 3 85 
consecutive initial injections and a mean of 2.3 injections between month 2 and 6 86 
based on OCT findings.  87 
 88 
Baseline mean BCVA was 50 ETDRS letters (20/100) ranging from 3 to 78 letters 89 
(20/800-20/26 -2). Within one day following the first injection, BCVA improved by 5 90 
letters (1 line / p < 0.01). At month 1 and 3, BCVA improved further to 60 letters 91 
(20/63) (p < 0.01) and 63 letters (20/50 -2) (p < 0.01) respectively. Up to month 6 92 
there was, compared to baseline, a mean improvement of 15 letters (3 lines) to 65 93 
letters (20/50) (p < 0.01). Figure 1 and figure 2 (left graph) illustrate the change in 94 
mean BCVA over time up to month 6. 95 
Mean CRT at baseline was 558 µm (range: 353 to 928 µm). CRT measurements one 96 
day, one week and one month after the first injection demonstrated a highly 97 
significant (p < 0.01) reduction of mean CRT to 401 µm, 323 µm and 331 µm 98 
respectively. At month 3, one month after the last of three initial injections, CRT 99 
remained stable at 328 µm (range: 180 – 625 µm). The OCT based retreatment 100 
regimen between month 3 and 6 led to a slight, but not significant increase in mean 101 
CRT to 382 µm (range: 185 – 808 µm) at month 6. Compared to baseline, CRT at 102 
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month 6 was still significantly (p < 0.01) reduced by a mean of 172 µm (range: - 579 103 
µm to + 111µm). Figure 1 and figure 2 (right graph) summarize the change of CRT 104 
over time. There was statistically significant correlation of improvement in BCVA and 105 
decrease in CRT (r = -0.49, p = 0.02).  106 
 107 
An analysis to reveal predictive factors for outcome found no significant correlation 108 
between the duration of RVO and improvement of BCVA (r = - 0.34; p = 0.11) or the 109 
decrease of CRT (r = 0.33; p = 0.12). Furthermore, neither the patients age (r = 0.07, 110 
p = 0.73), nor baseline BCVA (r = -0.37, p = 0.07) or baseline CRT (r = 0.17, p = 111 
0.41) appeared to have any predictive effect on BCVA outcome within the collective 112 
sample (BRVO and CRVO).  113 
 114 
Within 6 month, none of the patients showed any severe local adverse events such 115 
as uveitis, retinal detachment or endophthalmitis. None showed progression to 116 
ischemic BRVO/CRVO documented clinically as well as by FA imaging and no 117 
systemic complications such as thrombo-embolic events occurred.   118 
 119 
Subgroup analysis:  120 
Mean BCVA in the CRVO group (N = 8) was 35 letters (20/200) at baseline, and 47 121 
letters (20/125 + 2) at month 6. The improvement in vision was not statistically 122 
significant (p > 0.05).  Similarly, the reduction in mean CRT from 585 µm at baseline 123 
to 489 µm at month 6 was not statistically significant (p > 0.5). According to the study 124 
protocol a mean number of 4.8 out of 7 possible injections per patient were 125 
administered. For this subgroup, analyses with regard to possible predictive factors, 126 
revealed no correlation of BCVA outcome and age, baseline BCVA, baseline CRT, or 127 
duration of thrombosis. An angiographic example for CRVO treated with repeated 128 
1mg bevacizumab injections is shown in figure 3.  129 
The subgroup of eyes with BRVO (N = 21) showed a statistically significant (p < 130 
0.001) improvement in BCVA from a mean of 55 letters (20/80) to 70 letters (20/40) 131 
at month 6. Consistent with the recovery of retinal function, mean CRT decreased 132 
significantly (p < 0.001) from 547 µm at baseline to 349 µm at month 6. The 133 
restoration of retinal anatomy (CRT), as decrease in CRT, and the improvement of 134 
vision correlated significantly (r = -0.59; p = 0.01).  In this subgroup, 5.5 out of 7 135 
possible injections were required. Data analyses with respect to possible predictive 136 
factors identified the time interval between onset of thrombosis and therapy initiation 137 
correlating significantly (r = - 0.49, p = 0.03) with an improvement of vision. However, 138 
the level of a decrease of CRT did not significantly correlate with this time interval (r = 139 
0.22; p = 0.37). Further analyses revealed, that individuals with low BCVA at baseline 140 
achieved a higher benefit by the treatment than patients, which presented a higher 141 
BCVA at baseline (r = - 0. 54; p = 0.01). Baseline CRT had no significant impact on 142 
VA improvement (r = 0.38; p = 0.10).  Figure 4 shows a case of BRVO responding 143 
favourably to intravitreal bevacizumab therapy as documented by angiography and 144 
OCT. 145 
 146 
Discussion: 147 
 148 
Since anti-VEGF therapy has been approved for the therapy of neovascular age-149 
related macular degeneration (AMD), this approach seems appealing for treatment of 150 
other ocular diseases associated with VEGF, such as retinal vein occlusions (RVO). 151 
Our six- month data demonstrated promising functional and anatomic effects as well 152 
as no safety concerns. Mean VA improved by 3 lines and mean CRT measured by 153 
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OCT decreased by 171 µm at month 6. Significant benefits were seen as early as 154 
one day after injection. None of the patients developed neovascularization or showed 155 
signs of conversion into a non-perfusion type with ischemia-related complications. So 156 
far, no severe ocular adverse events such as retinal detachment or endophthalmitis 157 
were detected and the absence of any inflammation suggests that even repeated 158 
injections are well tolerated. None of the patients showed evidence of severe 159 
systemic adverse events such as arterial thromboembolic events. This prospective 160 
study was too small to provide conclusive data on safety, but had an estimated 161 
power of 95% to detect an adverse event with a rate of 9.7 % 23.  162 
However, the absence of local and systemic safety issues in our study is supported 163 
by a number of retrospective studies showing comparable results. 24-28  164 
Interestingly, subgroup analysis with regard to a significant improvement in VA and/or 165 
reduction in CRT due to the treatment with Bevacizumab showed no significant 166 
benefit for patients with CRVO. These results may be due to a relatively small 167 
number of patients in this subgroup, but this observation might as well indicate, that a 168 
larger amount of anti-VEGF antibodies is needed to obtain therapeutic results as 169 
seen in patients with BRVO. In this context it can be speculated that CRVO with 170 
larger areas of hypoperfusion lead to higher levels of VEGF expression, 13,14,29  171 
requiring an adjusted anti-VEGF dosage. The findings of our study with regard to 172 
CRVO are clearly limited due to the small CRVO subgroup. However, the findings in 173 
this group are potentially valuable indicators for new prospective studies on anti-174 
VEGF drugs in CRVO in the near future. 175 
Despite early results being promising, some questions remain unanswered. First of 176 
all, anti-VEGF therapy for RVO clearly represents a symptomatic treatment. Long- 177 
term follow-up is needed to show maintenance of beneficial effects obtained by local 178 
therapy. Our 6 months results indicate that compared to neovascular AMD, more 179 
frequent retreatment will be necessary to achieve satisfactory therapeutic effects. 180 
The study further implicated that not all patients respond equally well to intravitreal 181 
bevacizumab therapy. Statistical analyses were done to evaluate potential predictive 182 
factors for VA benefit. For patients presenting with CRVO we could not identify any 183 
association with age, onset of thrombosis and therapy initiation, baseline VA or 184 
baseline CRT. But, due to the small study sample, further investigation is obviously 185 
needed to provide comprehensive information. In the BRVO sub population, we 186 
found that patients with rather low visual function at baseline showed more treatment 187 
benefit than individuals with less compromised initial BCVA. Initial BCVA correlated 188 
well with initial CRT and, the improvement of vision correlated significantly with the 189 
decrease of CRT. In addition we found that shorter disease duration was positively 190 
correlated with more vision improvement 29. Patients with a long lasting pathology 191 
frequently showed good anatomical results, but did not gain vision; in contrast, 192 
patients who received treatment soon after the onset of the edema, presented with 193 
good anatomic and vision outcomes. These associations suggest that a long lasting 194 
pathology has led to irreversible retinal damage which cannot be restored merely by 195 
resolution of retinal edema. Levels of a variety of other angiogenic and inflammatory 196 
factors in the retina and/or vitreous are likely to be of importance.  197 
Detailed evaluation for possible long-term adverse events of anti VEGF agents are 198 
essential, even if previous studies showed no evidence of any toxicity of 199 
bevacizumab in the dosage used for ophthalmologic purposes 24,30-32. Since currently 200 
used therapies for retinal vein occlusions have achieved only limited success and 201 
implicate complications, anti VEGF therapy obviously seems to be a novel, 202 
innovative approach, which should be further evaluated in large, prospective, 203 
controlled clinical studies.  204 
205 
 group.bmj.com on February 19, 2010 - Published by bjo.bmj.comDownloaded from 
Intravitreal application of (Avastin®) in retinal vein occlusion. Kriechbaum et al. 7
Figure legends: 205 
 206 
Figure 1: Mean change in BCVA and CRT from baseline to month 6. “*” indicates 207 
follow-up visits at with significant improvement in BCVA and significant 208 
reduction in CRT as compared to baseline values. Error bars represent 209 
mean and 95 % confidence intervals.  210 
 211 
Figure 2: Left graph: Scatter plot of BCVA results at baseline (y-axis) compared 212 
to results after 6 months (x-axis). Circles represent individual outcomes. 213 
Circles above the 45 ° regression line indicate patients with improved 214 
BCVA after 6 months. Circles beneath the line represent patients who 215 
did not have vision improvement. Right graph: Scatter plot of CRT 216 
results at baseline (y-axis) compared to results at month 6 (x-axis). 217 
Circles above the 45 ° regression line represent patients showing 218 
decreased CRT. Circles beneath the line indicate patients with 219 
increased CRT despite treatment at months 6. 220 
 221 
Figure 3: Patient presenting CRVO in the left eye. This patient showed an 222 
excellent response to 4 injections of bevacizumab within 6 months.  223 
 224 
Figure 4:  Patient presenting with BRVO. After 3 intravitreal injections of 225 
bevacizumab further treatment was abandoned until the month 6 study 226 
visit, when edema recurred. 227 
 228 
229 
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